Abiomed will partner with select healthcare institutions for hemodynamic support training and patient management initiatives for heart muscle recovery through prophylactic Impella cardiac assist device-supported revascularization.
The partnership will establish heart muscle recovery programs that will help recover the native heart in patients. According to Danvers, Mass.-based Abiomed, previous data showed that 90 percent of survivors recovered native cardiac function and were discharged with their own heart when the Impella device was utilized. With Impella support, results of clinical trials have shown a 59 percent reduction in 30-day mortality in patients who received the device prior to revascularization.
According to Abiomed, PinnacleHealth in Harrisburg, Pa., will be the first institution to partner with the company. “This collaborative program will educate healthcare institutions across the U.S. on the value of treating patients with emergent hemodynamic support to allow earlier intervention that achieves the outcome of heart muscle recovery for their cardiac care programs,” said Michael R. Minogue, chairman, president and CEO of Abiomed.